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ABSTRACT 
Sexual dysfunctions are commonly seen in women on selective serotonin reuptake inhibitors 
(SSRIs). The complexities of female sexual functioning are reflected through modulation of 
inter- playing factors like the neuropsychophysiological factors, inter-personal and relationship 
issue, psychiatric co-morbidities and physical disorder. The incidence of SSRIs-induced FSD 
is difficult to estimate because of the potential confounding effects of SSRIs, presence of 
polypharmacy, marital effect, socio-cultural factors and due to the design and assessment 
problems in majority of the studies. The exact mechanism of FSD-induced SSRIs is unknown. 
It has been postulated that although SSRIs may modulate other neurotransmitter system such 
as nitric oxide (NO), noradrenergic and dopamine in inducing FSD. In the present review, we 
highlight current evidence regarding potential mechanism of SSRIs in causing FSD, which 
include low sexual desire (low libido), arousal difficulties (lack of lubrication), and 
anorgasmia. The specific association of FSD to SSRI use, has not been ellucidated. The 
relationship is dose-dependent, and may vary among the groups with respect to mechanism of 
serotonin and dopamine reuptake, induction of release of prolactin from the pituitary gland, 
anticholinergic side-effects, inhibition of NO synthesis and emotional-memory circuit 
encryption for sexual experiences. Various interventional strategies exist regarding the 
treatment of SSRI-induced FSD and this includes tolerance, titration dosage, substitution to 
another antidepressant drug and psychotherapy. There is a need of better understanding of 
SSRIs-induced FSD for better treatment outcome. 
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